This compound is primarily utilized in the development of antibody-drug conjugates (ADCs), where it serves as a linker to connect cytotoxic drugs to antibodies. The azide group enables click chemistry reactions, facilitating efficient and selective conjugation. The Val-Cit dipeptide sequence is cleavable by cathepsin B, an enzyme overexpressed in many cancer cells, allowing for targeted drug release. The PAB (para-aminobenzyl) spacer enhances the stability of the linker, while the PNP (p-nitrophenyl) group acts as a leaving group during the conjugation process. This design ensures precise delivery of therapeutic agents to cancer cells, minimizing off-target effects and improving treatment efficacy.